The 'slimming elixir' has exceeded expectations! Novo Nordisk Q3 achieved record high revenue and profits
芊芊551
发表于 2023-11-2 17:37:49
228
0
0
On Thursday (November 2nd) local time, Danish pharmaceutical giant Novo Nordisk released its third quarter financial report, with record revenue and profit, and sales of the popular weight loss drug Wegovy exceeded expectations.
According to the financial report, Novo Nordisk Q3 sales amounted to 58.73 billion Danish kroner (approximately 8.34 billion US dollars), a year-on-year increase of 29%; The operating profit (EBIT) was DKK 26.91 billion (approximately USD 3.82 billion), a year-on-year increase of 33%; Both data exceeded market expectations.
(Source: Company website)
Wegovy, which is highly concerned by the market, had sales of DKK 9.648 billion (approximately $1.37 billion) in the third quarter, exceeding the market's expected DKK 8.07 billion.
Novo Nordisk stated in a statement that although Wegovy's supply capacity is gradually expanding, it will continue to restrict the supply of low-dose drugs in the United States to ensure the treatment of existing patients.
The company revealed that it had applied to US and EU authorities in September and October to approve Wegovy for reducing cardiovascular disease risk.
In August this year, Novo Nordisk stated that supply restrictions are likely to continue until 2024. Investors and analysts have asked the company to clarify when the supply issue can be resolved, as competitor Lilly expects its weight loss drug Mounjaro to receive US approval later this year.
Novo Nordisk's Wegovy and Lilly's Mounjaro are currently the most widely discussed weight loss drugs on the market, both of which belong to the new class of GLP-1 (glucagon like peptide-1) receptor agonists. Taking these GLP-1 drugs can lower blood sugar levels, increase satiety, and help control appetite and weight. In addition, Wegovy's "sisters product" and Ozempic, which is used to treat diabetes, have also attracted much attention.
Goldman Sachs released a forecast last month that by 2030, the annual sales of the global weight loss drug market may increase to around $100 billion, while Lilly and Novo Nordisk will form a duopoly, with these two pharmaceutical companies accounting for about 80% of the market share.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- NIO's Q2 revenue and delivery volume hit new highs
- NIO releases second quarter financial report with revenue of 17.45 billion yuan, and the US stock market closed up more than 14% on the same day
- NIO's Q2 revenue of 17.45 billion yuan, Li Bin: Optimizing gross profit margin is an important task for the next stage
- NIO opens nearly 15%, second quarter revenue hits historic high
- Strong Apple A18 orders drive TSMC's 3nm process to increase revenue by 34% year-on-year this year
- JD Xiaoku has accumulated over 10 billion yuan in revenue for users
- Douyu's Q2 revenue was 1.032 billion yuan
- Douyu: Total revenue of 1.032 billion yuan in Q2 2024
- Douyu: Q2 total revenue of 1.032 billion yuan, adjusted net loss of 45.5 million yuan
- In the first half of 2024, Huize achieved a total revenue of 590 million yuan
-
9月が終わり、映画・テレビ業界が暗躍している。最近、愛奇芸の創始者でCEOのGONG宇氏は、映画・テレビ業界が長短の変化、AIの変化、中国映画・テレビドラマの海外進出の変化の3つの変化を経験していると発表した。 ...
- 寒郁轩良
- 昨天 14:17
- 支持
- 反对
- 回复
- 收藏
-
8月のトヨタ自動車(ダイハツ自動車と日野自動車を除く、レクサスを含む)の世界生産台数は前年同月比11.2%減の709571台、世界販売台数は前年同月比3.1%減の826863台だった。 日本本土市場では、トヨタ自動車の8月 ...
- SOGO
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
ネットワーク状況監視サイトDownDetectorによると、オーディオストリーミングプラットフォームSpotifyは日曜日に約3時間にわたる障害を経験した後、正常に回復し、ピーク時には米国の4万人以上のユーザーに影響を与 ...
- hecgdge4
- 昨天 09:33
- 支持
- 反对
- 回复
- 收藏
-
百済神州(688235.SH)はA株の有名な革新薬企業で、2017-2024年上半期、同社の各期の研究開発投資はA株の化学製薬会社(申万二級)の中で最も高く、研究開発費用は合計600億元を超えた。 しかし、百済神州にとって ...
- wylz8473
- 前天 18:36
- 支持
- 反对
- 回复
- 收藏